Many clinical trials have been set up to treat COVID‐19 by targeting pathways relating to proinflammatory cytokine production, for example, IL‐1 and IL‐6 (Bonam, Kaveri, Sakuntabhai, Gilardin, & Bayry, 2020; Merad & Martin, 2020). This evidence concerns the gene IL1B and COVID-19.